AASLD
<ѻý class="page-description">American Association for the Study of Liver Diseasesѻý>At highest dose, thyroid hormone receptor-beta agonist decreased liver fat content by 45%
1-year survival reached 78% for patients who received an emergency transplant
In randomized trial, oral elafibranor induced biochemical response at 1 year in 51% of patients
Results highlight the importance of prompt recognition and treatment of acute kidney injury
AASLD president: "No way we are going to be able to transplant our way out of this"
Latest REGENERATE analysis comes on heels of REVERSE flop
Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH
With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon
Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH
Ileal bile acid transporter inhibitor could become second drug for PFIC
Significant improvements in itching, bile acid levels for rare, life-threatening liver disorder
Phase II data suggest drug is well-tolerated and can reduce cravings in this group of patients
100% success rate even without the use of hepatitis B immunoglobulin
Patients who kept their blood pressure under 140/90 mm Hg had better kidney function at 1 year
-
AASLD: American Association for the Study of Liver Diseases
November 2024
-
ACG: American College of Gastroenterology
October 2024
-
EASL: European Association for the Study of the Liver
June 2024
-
DDW: Digestive Disease Week
May 2024